CALA insider filings
Calithera Biosciences, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-05-26. Screen CALA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CALA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Calithera Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-05-26 | 4 | TAKEDA PHARMACEUTICAL CO LTD Takeda Ventures, Inc. — 10% owner | Other (J): 1,000,000 (derivative) | EDGAR |
| 2023-01-31 | 4 | PAKIANATHAN DEEPIKA — Director | Sale (S): 120,161 @ $0.39 · Sale (S): 1,172 @ $0.39 | EDGAR |
| 2023-01-25 | 4 | Sjogren Eric — SR. VP, DRUG DISCOVERY | Tax withholding (F): 279 @ $0.45 | EDGAR |
| 2023-01-25 | 4 | Kuriakose Emil — CHIEF MEDICAL OFFICER | Tax withholding (F): 79 @ $0.45 | EDGAR |
| 2023-01-25 | 4 | Molineaux Susan — PRESIDENT & CEO, Director | Tax withholding (F): 526 @ $0.45 | EDGAR |
| 2023-01-25 | 4 | Wong Stephanie — See Remarks | Tax withholding (F): 317 @ $0.45 | EDGAR |
| 2023-01-25 | 4 | Molineaux Christopher — SR. VP, DEVELOPMENT | Tax withholding (F): 217 @ $0.45 | EDGAR |
| 2022-07-06 | 4 | TAKEDA PHARMACEUTICAL CO LTD — 10% owner Takeda Ventures, Inc. — 10% owner | Other (J): 1,000,000 (derivative) @ $0 · Other (J): 1,000,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | JONES SUZY — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | AGARWAL SUNIL — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Garland J. Scott — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Wise Blake — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Orford Keith — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Wolff Henry Ward — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Molineaux Susan — PRESIDENT & CEO, Director | Grant/award (A): 597,475 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Wong Stephanie — See Remarks | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Ray Sumita — See Remarks | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Sjogren Eric — SR. VP, DRUG DISCOVERY | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Parlati Francesco — SR. VP, RESEARCH | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Molineaux Christopher — SR. VP, DEVELOPMENT | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Orford Keith — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-01-27 | 4 | Kuriakose Emil — CHIEF MEDICAL OFFICER | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2022-01-25 | 4 | Parlati Francesco — SR. VP, RESEARCH | Tax withholding (F): 4,794 @ $0.49 | EDGAR |
| 2022-01-25 | 4 | Wong Stephanie — See Remarks | Tax withholding (F): 5,586 @ $0.49 | EDGAR |
| 2022-01-25 | 4 | Sjogren Eric — SR. VP, DRUG DISCOVERY | Tax withholding (F): 4,794 @ $0.49 | EDGAR |
| 2022-01-25 | 4 | Kuriakose Emil — CHIEF MEDICAL OFFICER | Tax withholding (F): 666 @ $0.49 | EDGAR |
| 2022-01-06 | 4 | Parlati Francesco — SR. VP, RESEARCH | Tax withholding (F): 18,077 @ $0.66 | EDGAR |
| 2022-01-06 | 4 | Kuriakose Emil — CHIEF MEDICAL OFFICER | Tax withholding (F): 3,855 @ $0.66 | EDGAR |
| 2022-01-06 | 4 | Sjogren Eric — SR. VP, DRUG DISCOVERY | Tax withholding (F): 18,077 @ $0.66 | EDGAR |
| 2022-01-06 | 4 | Wong Stephanie — See Remarks | Tax withholding (F): 18,077 @ $0.66 | EDGAR |
| 2021-11-12 | 4 | Orford Keith — Director | Sale (S): 30,000 @ $0.86 · Sale (S): 48,190 @ $0.88 | EDGAR |
| 2021-11-10 | 4 | Molineaux Susan — PRESIDENT & CEO, Director | Purchase (P): 100,000 @ $0.85 | EDGAR |
| 2021-11-10 | 4 | DRACHMAN JONATHAN G — Director | Purchase (P): 200,000 @ $0.86 | EDGAR |
| 2021-11-10 | 4 | Molineaux Christopher — SR. VP, DEVELOPMENT | Purchase (P): 100,000 @ $0.85 | EDGAR |
| 2021-11-09 | 4 | Orford Keith — Director | Grant/award (A): 30,000 @ $0 · Sale (S): 51,810 @ $0.84 | EDGAR |
| 2021-11-09 | 4 | Molineaux Christopher — SR. VP, DEVELOPMENT | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2021-11-09 | 4 | Sjogren Eric — SR. VP, DRUG DISCOVERY | Grant/award (A): 30,000 @ $0 · Tax withholding (F): 15,566 @ $0.87 | EDGAR |
| 2021-11-09 | 4 | Wong Stephanie — See Remarks | Grant/award (A): 30,000 @ $0 · Tax withholding (F): 15,566 @ $0.87 | EDGAR |
| 2021-11-09 | 4 | Ray Sumita — See Remarks | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2021-11-09 | 4 | Kuriakose Emil — CHIEF MEDICAL OFFICER | Grant/award (A): 12,000 @ $0 · Tax withholding (F): 3,077 @ $0.87 | EDGAR |
| 2021-11-09 | 4 | Parlati Francesco — SR. VP, RESEARCH | Grant/award (A): 30,000 @ $0 · Tax withholding (F): 15,566 @ $0.87 | EDGAR |
| 2021-10-29 | 4 | Sjogren Eric — SR. VP, DRUG DISCOVERY | Grant/award (A): 90,000 @ $0 · Tax withholding (F): 45,965 @ $1.89 | EDGAR |
| 2021-10-29 | 4 | Orford Keith — CHIEF MEDICAL OFFICER | Grant/award (A): 90,000 @ $0 | EDGAR |
| 2021-10-29 | 4 | Molineaux Christopher — SR. VP, DEVELOPMENT | Grant/award (A): 36,000 @ $0 | EDGAR |
| 2021-10-29 | 4 | Wong Stephanie — See Remarks | Grant/award (A): 90,000 @ $0 · Tax withholding (F): 45,965 @ $1.89 | EDGAR |
| 2021-10-29 | 4 | Ray Sumita — See Remarks | Grant/award (A): 36,000 @ $0 | EDGAR |
| 2021-10-29 | 4 | Parlati Francesco — SR. VP, RESEARCH | Grant/award (A): 90,000 @ $0 · Tax withholding (F): 45,965 @ $1.89 | EDGAR |
| 2021-06-14 | 4 | George Jean — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Calithera Biosciences, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-01-25 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-01-09 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-09-29 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2022-08-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-14 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2022-05-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-12 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CALA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs